The MHCII locus includes genes encoding classical MHCII proteins that bind peptide antigens and present them to T cells, interspersed with genes for nonclassical MHCII proteins that have accessory roles in the antigen-loading process. The nonclassical MHCII protein DM (HLA-DM in humans, H-2M or H2-DM in mice) has a well-understood function in catalyzing peptide exchange on MHCII proteins 1,2 . MHCII proteins assemble in the endoplasmic reticulum (ER) with an invariant-chain chaperone that occupies the peptide binding site and escorts bound MHCII to endosomal compartments, where the chaperone is degraded by endosomal proteases, leaving a nested set of short peptides (CLIP) in the MHCII binding site 3 . DM acts to catalyze exchange of CLIP for endosomal peptides derived from endogenous proteins or endocytosed material 1 . The MHCIIpeptide complexes are trafficked to the cell surface for inspection by CD4 + T cells as part of the system of antigen presentation and immune surveillance. In the absence of DM, many MHCII proteins do not exchange peptides and remain bound to CLIP, so that DM-deficient cells are defective in antigen presentation 4,5 . The molecular mechanism by which DM catalyzes peptide exchange on MHCII is not clear, but current ideas focus on stabilization of a MHCIIpeptide intermediate with disrupted peptide main chain hydrogen bonds or side chain pocket interactions [6] [7] [8] [9] [10] . DM has another role in stabilizing peptide-free empty MHCII molecules against irreversible inactivation 2,11-13 , presumably by binding to a peptide-free MHCII form and stabilizing a receptive conformation.
a r t i c l e s
The MHCII locus includes genes encoding classical MHCII proteins that bind peptide antigens and present them to T cells, interspersed with genes for nonclassical MHCII proteins that have accessory roles in the antigen-loading process. The nonclassical MHCII protein DM (HLA-DM in humans, H-2M or H2-DM in mice) has a well-understood function in catalyzing peptide exchange on MHCII proteins 1, 2 . MHCII proteins assemble in the endoplasmic reticulum (ER) with an invariant-chain chaperone that occupies the peptide binding site and escorts bound MHCII to endosomal compartments, where the chaperone is degraded by endosomal proteases, leaving a nested set of short peptides (CLIP) in the MHCII binding site 3 . DM acts to catalyze exchange of CLIP for endosomal peptides derived from endogenous proteins or endocytosed material 1 . The MHCIIpeptide complexes are trafficked to the cell surface for inspection by CD4 + T cells as part of the system of antigen presentation and immune surveillance. In the absence of DM, many MHCII proteins do not exchange peptides and remain bound to CLIP, so that DM-deficient cells are defective in antigen presentation 4, 5 . The molecular mechanism by which DM catalyzes peptide exchange on MHCII is not clear, but current ideas focus on stabilization of a MHCIIpeptide intermediate with disrupted peptide main chain hydrogen bonds or side chain pocket interactions [6] [7] [8] [9] [10] . DM has another role in stabilizing peptide-free empty MHCII molecules against irreversible inactivation 2, [11] [12] [13] , presumably by binding to a peptide-free MHCII form and stabilizing a receptive conformation.
The other nonclassical MHCII protein, DO (HLA-DO in humans, H-2O in mice), is also involved in antigen presentation, although its role is less well-defined than that of DM. Expression of genes encoding MHCII, DM and other proteins involved in MHCII antigen presentation are coordinately regulated by the class II transactivator CIITA, but DOβ has additional regulatory elements 14 . As a result, DO has a unique expression pattern, being expressed principally in B cells, thymic medullary epithelial cells, trophoblasts and a subset of dendritic cells [15] [16] [17] . In B cells and dendritic cells, DO expression is developmentally regulated, with expression downregulated as B cells enter germinal centers for affinity maturation and class switching 18, 19 , and as dendritic cells mature into fully stimulating professional antigenpresenting cells able to activate naive T cells 16, 20 . This expression pattern has suggested a role for DO in promoting tolerance to selfantigens 21, 22 , an idea supported by the suppression of autoimmune diabetes in H-2O transgenic non-obese diabetic mice 23 . DO-knockout mice have a different spectrum of MHCII-bound peptides than that observed for DO-sufficient mice 24 , and DO transfection alters the repertoire of MHCII-bound peptides in a human melanoma line 25 . Finally, antigen-presentation function is altered in DO-deficient mice 24, [26] [27] [28] . Antigens can access endosomal or lysosomal compartments for entry into the MHCII presentation pathway via fluid-phase endocytosis or receptor-mediated uptake. Studies with DO-deficient mice have shown that the relative efficiency of MHCII presentation via these pathways is affected by DO, with DO typically promoting B-cell receptor-mediated uptake, although differences have been observed for different epitopes and MHCII alleles 24, [26] [27] [28] .
On a molecular basis, most studies point to a role for DO in inhibiting DM function. In vitro experiments generally have shown that the a r t i c l e s DO-DM complex is inactive in catalyzing peptide exchange 25, [29] [30] [31] . DO has been shown to block DM function in DO-transfected antigenpresenting cells 29 . In addition, in mice overexpressing DO the cell surface level of MHCII-CLIP is increased 32 , as it is in human DO transfectants 25 , similar to the effect seen in DM-knockout cell lines and DM-deficient mice.
The three-dimensional structure of DO is not known, although it has been modeled on the basis of homology to classical MHCII proteins 31, 33 . Here we set out to determine how DO modulates HLA-DM function. We determined the X-ray crystal structure of HLA-DO bound to HLA-DM and studied DO function through enzyme kinetics and mutagenesis studies. In the crystal structure, the DO and DM molecules bind in a side-by-side arrangement similar to that proposed for the complex of MHCII with DM. The DO-DM interface observed in the crystal structure is congruent with the MHCII-DM interface predicted from mutagenesis studies, and DM mutants have similar effects on DO binding and MHCIIpeptide exchange. Moreover, kinetic studies showed that DO acts as a competitive inhibitor of DM. Together, these results show that DO functions as a substrate mimic by binding tightly to DM and preventing MHCII access. These findings place constraints on potential functional roles for DO.
RESULTS

DO inhibition of DM-mediated peptide binding and release
In vivo, DO forms a tight complex with DM 30 . In the absence of DM, DO is retained in the ER and degraded 30 . Because of this, most previous studies of DO function have focused on characterization of DO-DM complexes isolated from native or recombinant expression systems 25, 29, 34 . From a mechanistic point of view, studies with isolated DO-DM complexes are limited because the concentrations of DM and DO cannot be independently varied. For our studies we were able to prepare the extracellular domain of human DO independently of DM by expression in Drosophila melanogaster S2 cells, using either an Ig-fusion protein (sDO-Fc) or a C-terminal leucine zipper (szDO) to stabilize the DO αβ heterodimer (Fig. 1a) . In some experiments, Pro10a of the α subunit was mutated to alanine (αP10aA; szDOv and sDOv constructs), as a valine mutation at this position has previously been reported to stabilize DO folding in the absence of DM 35 . (In the original characterization of this mutation the position is labeled αPro11, but here we use the canonical MHCII numbering system, in which the position is labeled αPro10a to maintain concordance with the numbering of the remainder of the MHCII α subunit.) In size-exclusion chromatographic analysis, the purified DO and DM showed the expected molecular weights, without evidence of aggregation, as did the soluble DO-DM complex prepared by coexpression of sDO-Fc and the soluble ectodomain of DM (sDM) after removal of the Fc portions (Fig. 1b) . The inhibitory activities of DO-Fc, sDOv (carrying the αP10aA mutation) and zippered szDOv were similar (Supplementary Fig. 1 ). We measured the interaction of soluble DO and DM using biolayer interferometry. DM showed dose-dependent, saturable, tight binding to szDO (Fig. 1c) . With increasing concentration, DO was able to completely inhibit DM catalysis of peptide binding (Fig. 1d) . We also evaluated DO's ability to inhibit DM-catalyzed peptide release from a preformed MHCII-peptide complex. Dosedependent inhibition of DM-mediated peptide release was observed (Fig. 1e) . Thus, DO can inhibit both the activity of DM in promoting peptide binding to MHCII molecules and its facilitation of peptide release from MHCII-peptide complexes.
Overview of DO-DM complex
To understand the mechanism by which DO inhibits DM, we determined the 3.2-Å crystal structure of the DO-DM complex using DMα, DMβ, DOα-Fc and DOβ-Fc subunits coexpressed in Table 1 ). Electron density for essentially all of DM and DO was observed except for a short section (DM β142-145). The two copies of the DO-DM complex present in the crystallographic asymmetric unit showed little difference. DM binds to DO in a side-by-side arrangement, with three areas of contact involving each of the domains of the proteins (Fig. 2a,b) . In general, the structure of DM is essentially identical to those previously determined for DM alone [36] [37] [38] , with one exception (see below). Notably, the structure of DO is distinct from that of DM and most similar to those previously determined for classical MHCII proteins ( Fig. 2a and Supplementary Fig. 2 ), but with differences in the α subunit's 3 10 helix and adjacent extended strand region (described below).
In the DO-DM complex, the DM molecule rides on top of DO so that residues underneath DM's β-sheet platform contact residues above the end of DO's β-sheet platform (Fig. 2a,b) . DM binds DO using the large concave surface underneath the end of the DM β-sheet platform, a surface that includes edges of both membrane-proximal immunoglobulin (Ig) domains (Fig. 2b) . Overall, DM and DO associate tightly, and the complex three-part interface creates an extensive buried surface area of ~2,800 Å ( Fig. 2c and Supplementary Table 1 ). The interaction is distinct from that described for other MHCII proteins binding to partners such as αβTCR, CD4 or bacterial superantigens, or to another MHCII protein in the crystallographic dimer of MHCII molecules. It also differs from that of classical and nonclassical MHCI proteins binding to partners such as TfR, Fc, TCRγδ or NK receptors.
Interactions between DO and DM
Interface I is the largest of the three main areas of contact between DM and DO, with about half of the total buried surface area ( Fig. 2 and Supplementary Table 1 ). The major feature of this interface is the extended linker connecting DM's α1 and α2 domains (residues α91-100), a portion of which aligns with the last β-strand (s4) of DO's β-sheet platform (Fig. 2d) . The side chains of DM residues flanking the extended linker protrude into depressions in the DO surface (Fig. 2e) . Pro95 of the DM α subunit (DM αPro95) fits into the cleft proximal to the α1-helix of DO, and DM αPhe100 fits in a large cavity formed between the upper peptide-binding domain and the lower Ig domain of DO. In the center of this region, DM αArg98 and DO αGlu40 make a salt bridge. In a reciprocal interaction, DO aromatic side chains αTrp43 and αPhe51, which flank the DO α subunit's 3 10 helix, fit into depressions in the DM surface (Fig. 2e) . Residues at the end of DMβ's β-strand platform and in the loop at the end of the DMβ1 helix participate in these interactions, including residues previously identified as the 'acidic patch' (βAsp31 and βGlu47) involved in the interaction with DR 39 .
Interface II involves residues from the membrane-proximal Ig domains of the α subunits of DM and DO (Fig. 2d) . This predominantly hydrophobic interface contributes about one-third of the total buried surface area of the complex. Nonpolar residues exposed on the surface of the last two β-strands of the Ig domain (α173-194) of DM form a hydrophobic ridge, against which lie three loops at the membrane-proximal end of the DO Ig domain (α100-103, α129-134 and α151-153).
Interface III involves residues from the Ig domains of the β subunits of DM and DO, and it accounts for less than 20% of the total buried surface area (Fig. 2d) . Its major feature is a complementary electrostatic interaction involving the DM βArg110 and DO βGlu187 residues. Structurally, the arrangement in this interface is the reciprocal of interface II: residues from a DM loop connecting β-strands in the Ig domain (β107-110) contact residues from DO (β96-100, β180-181 and β183-187) exposed on the face of the Ig-domain β-strand. A small disordered region in DM's Ig domain (β142-145) is near the interface (Fig. 2d , dashed line, and Supplementary Fig. 3 ). Depending on its conformation, this segment might be able to mediate additional DO contacts.
DO adopts an MHCII fold with a subunit alterations
The DO-DM structure reveals an overall topology for DO highly similar to that of classical MHCII molecules such as HLA-DR1 (DR; Fig. 3a) . For the α subunit, DO superimposes well with both DR and HLA-DQ1 (DQ), with substantial Cα-backbone differences limited to the two structural elements that flank the 3 10 helix-that is, the last strand in the β-sheet platform (s4) and the extended region between the 3 10 helix and the long α1-helical region. For the β subunit, DO superimposes well with DR and DQ throughout the sequence, with essentially no changes, except for a flexible loop (β106-11) in the Ig domain that adopts different conformations in the various MHCII structures determined to date 36, 38 .
The backbone differences in the α subunit have two consequences for the overall structure of the DO protein. The first is the zipping up of the β-sheet platform between strands S2 and S3 (Fig. 3b) . In DR, DQ and other MHCII proteins, the last two strands in the α subunit's β-sheet platform veer away from the others (Fig. 3b, right) . In DO, strands S3 and S4 together shift ~2 Å toward S2, forming a continuous hydrogen bonding network between strands of the β-sheet platform (Fig. 3b, left) . The structural change aligns DO strand S4 so that it can pair with DM (α96-99), which extends the continuous β-sheet platform by one strand. 
r t i c l e s
The second consequence is a rearrangement of aromatic residues in the vicinity of the 3 10 helix and adjacent extended strand region (Fig. 3c) . In DR and other MHCII proteins, this region interacts with bound peptide, with the extended strand participating in peptide main chain interactions and αTrp43, αPhe54 and βPhe89 lining the P1 peptide side chain-binding pocket (Fig. 3c, right) . In DO, the 3 10 helix tilts (~12°) and the last turn partially unwinds. The first turn of the α1 helix also unwinds. As a consequence of the unwinding of both flanking helices, the extended strand is lengthened and undergoes a conformational change, displacing αPhe51 about 7 Å and allowing the αTrp43 side chain to flip out (Fig. 3c, left) . In DR and other MHCII proteins, αTrp43 is tucked into the hydrophobic core lining the P1 pocket and unable to make contact with the DM molecule. In DO, αPhe54 has moved (5 Å) into the region corresponding to the P1 pocket, displacing βPhe89, which flips out to the solvent previously occupied by αPhe51. Both αTrp43 and αPhe51 side chains thus become highly exposed on the outer face of DO and participate in key interactions with DM residues, forming the cornerstone of interface I (Fig. 3c) .
DO has a β-bulge in the first β-strand of the α subunit that results in disruption of the hydrogen bonding pattern at the center of the β-sheet platform (Fig. 3d) . For the human MHCII proteins DR and DP, and their murine homolog I-E, continuous hydrogen bonding between the α subunit (s1) and β subunit (s5) strands stabilizes the canonical antiparallel β-sheet conformation in this region. For the other human MHCII protein DQ and its murine homolog I-A, the β-bulge is present but allows the same number of hydrogen bonds. For DO, the inserted residue is proline, present as the cis isomer, which orients the carbonyl oxygen in a position that disrupts the hydrogen bonding pattern and destabilizes interaction between the two chains. Substitution of αPro10a by valine allows DO to egress the ER in the absence of DM 35 , presumably by restoring the canonical hydrogen bonding pattern in the β-bulge region and stabilizing DO αβ chain pairing.
DM does not change conformation upon binding to DO
DM does not undergo a major conformational change upon binding to DO. Structural comparison of DM in the DO-DM complex reported here with previously determined structures for HLA-DM and the murine homolog H2-M reveal Cα r.m.s. deviation of only 0.7 Å 2 , with essentially no overt conformational change in DM induced by DO binding, including in the extended α1-α2 linker that aligns along the DO β-strand platform in the DO-DM complex ( Supplementary Fig. 3a-c) . The only exception is the fourth β-strand (β131-149) in the membrane-proximal IgG domain of the DM β subunit (Supplementary Fig. 3d ). In the free HLA-DM structure, this strand adopts a zigzag conformation unusual among C-type IgG domains, with a large bulge (β131-136) interrupting the pattern of hydrogen bonds to the adjacent strand (Supplementary Fig. 3d ). In the DO-DM structure, this strand adopts a different conformation, crossing over to the other sheet directly, as observed in the structure of the mouse DM homolog H-2DM. A small disordered region (β142-145) follows the crossover; despite the disorder, it is evident that this region does not follow the same path as in the HLA-DM-only structure (Supplementary Fig. 3e ). Thus this region seems to be somewhat flexible. The region is near interface III.
DM interacts similarly with MHCII and DO
The biological role of DM is to catalyze peptide exchange on MHCII proteins, and several studies have identified amino acid residues important to the interaction of DM with MHCII 6, 39, 40 . Because of the close structural similarity of MHCII and DO, we mapped these residues onto the structure of the DO-DM complex (Fig. 4) . Notably, essentially all of the residues implicated in DM-MHCII interaction map to the interface between DM and DO, with most residues corresponding to direct DO-DM contacts. Each of the three interfaces is involved. Thus, the sites where DM interacts with MHCII, as identified in earlier mutagenesis studies, map very closely to the sites of DO-DM interaction, as observed in the crystal structure. 
r t i c l e s
To test the hypothesis that DM interacts similarly with MHCII and DO, we evaluated the effect of several mutations of DM introduced at the putative MHCII interaction surface, as defined by previous studies, and also on a distal surface as a control (Fig. 5a) . For each mutant, we measured the relative DO-DM affinity using biolayer interferometry (Fig. 5b) and the effect on DM-catalyzed peptide exchange (Fig. 5c) . For most mutants-those that preserved sufficient DM function-we also measured DO inhibition of DM (Fig. 5d) . The greatest effect was observed for the αR98E αR194E mutation (interfaces I and II): this mutation reduced DO-DM binding affinity to one-four-hundredth of the value for wild-type DM and completely blocked DM-DR interaction, as measured in a functional assay. DO binding and DR interaction were also substantially reduced by mutations βE8K or βE8A (periphery of interface I); βL32N, which introduces an aberrant glycan at β32 (interface I, acidic patch); and βR110S, which introduces an aberrant glycan at βAsn108 (interface III). Controls bearing the surface mutations βE39K βE183K βD188K or βE177N βI79T, which introduces an aberrant glycan at β177, had activity comparable to that of wildtype sDM in both assays. Together, the results show that these DM mutations have very similar effects on interaction with DO and with MHCII, supporting a competitive mechanism for DO inhibition and a shared binding site for DO and MHCII.
One mutation had differential effects on interaction with DO and DR, a double alanine substitution of DM βHis141 and βSer142, which flank the beginning of the flexible β2 region (β142-145; Supplementary Fig. 3 ). This mutation reduced DO binding and was resistant to DO inhibition, but the mutant had essentially wild-type function in catalyzing peptide loading on DR (Fig. 5b-d) .
To evaluate whether this phenomenon extended further into the disordered loop, we made additional mutations: two at position β144 (βA144E and βA144V) and also βH145N, which adds a glycan at this position. All three mutants had normal function in the assay In DR, strands S2 and S3 partially splay apart, disrupting the continuous hydrogen bonding pattern. In DO, S3 is closer to S2, allowing canonical antiparallel hydrogen bonding, and the sheet is extended with a strand from DM α96-99 (blue). (c) Difference in the 3 10 helix and adjacent extended strand. In DO, the extended region includes residues α49-60 (green). In DR, both the 3 10 and α1 helices are longer by approximately one turn and the extended region corresponds to residues α51-56. The side chains of DO residues αPhe51 and αTrp43 are flipped away from the rest of the structure and fit into pockets in DM, and the side chain of residue αPhe54 occupies the position corresponding to the MHCII P1 pocket. In DR, these residues are found tucked into the structure in a different arrangement that lines the P1 peptide side chain-binding pocket. (d) Subunit interface in the center of the β-sheet platform of DO, in the region around αPro10a where a β-bulge is formed. The bulge is present in DO, absent in DR1, and present in DQ1 but with an additional hydrogen bond. (Fig. 5c) and showed normal interaction with DO (Fig. 5b,d ). The basis for the different effects of the DM βH141A βS142A mutation on interaction with DO and DR is currently not clear.
Steady-state inhibition studies
The structural and mutagenesis data presented above suggest that DO binds to the site used for catalysis of MHCII-peptide exchange, and thus might act as a competitive inhibitor. We used a steady-state enzyme kinetics approach to characterize the nature of DO inhibition of DM. The catalytic activity of DM in promoting both peptide binding to and release from MHCII molecules can be described using a Michaelis-Menten formalism 41 (Fig. 6a) . These kinetic parameters were altered in the presence of DO (Fig. 6b) . DO inhibition of DM action could be competitive, with DO binding to same site as the MHCII substrate and preventing its binding, or noncompetitive, with DO binding at a different site from MHCII and inducing a conformational change that prevents catalysis while still allowing MHCII binding (Fig. 6c) . An uncompetitive mechanism, in which DO would bind only to a DM-MHCII complex, is unlikely as the DO-DM complex can form in the absence of MHCII.
A potential complication in analysis of enzyme inhibition is tightbinding inhibition, which interferes with conventional K m and V m analysis 42 . Tight-binding inhibition can occur when the active enzyme concentration is approximately greater than or equal to the apparent inhibition constant (K i app ) 43 and can be identified by a linear dependence of the median inhibitory concentration (IC 50 ) on enzyme concentration when substrate is near the K m and the IC 50 is within an order of magnitude of the total enzyme concentration 42 . To test for tight-binding inhibition, we determined the IC 50 values of sDO-Fc inhibition at a range of sDM concentrations (Fig. 6d) . The IC 50 values increased linearly with sDM concentration, with K i app (0.29 ± 0.02 µM; see Online Methods) in the range of the sDM concentrations tested. This suggests that sDO exhibits tight-binding inhibition. Many tight-binding inhibitors have a slow onset. However, overnight preincubation of reaction components before peptide addition had no effect on the peptide binding rate (data not shown).
Competitive, noncompetitive and uncompetitive mechanisms in the presence of tight-binding inhibition can be differentiated by the Morrison analysis 42 , in which the dependence of initial rate on substrate and inhibitor concentrations is described in terms of a K i app that shows different concentration dependence for the different inhibition mechanisms (see Online Methods). Association data (Fig. 6e) were globally fitted to the equations of the various inhibition models with statistical evaluation of model likelihood (see Online Methods).
Relative to an uncompetitive model, the competitive model was preferred (P < 0.001). For a noncompetitive model, the parameter α, describing the degree of completion (see Supplementary Note), refined to a very large value (>1,000), and the competitive model was still preferred, with a probability ratio of 3:1. For a purely noncompetitive model (α = 1), the competitive model was preferred (P < 0.001). We performed the same type of analysis using peptide dissociation data (Fig. 6f) . These data had greater uncertainty, particularly at high MHCII-peptide concentration, limiting the confidence of model discrimination. However, the same pattern was observed, with the competitive model preferred over uncompetitive and noncompetitive models, and with α refining to a very high value. Thus, for both dissociation and association reactions, DO inhibition of DM catalysis was most consistent with a competitive inhibition model.
DISCUSSION
The crystal structure, mutagnesis and kinetic studies reported here provide a molecular mechanism for DO action: DO mimics an intermediate in the MHCII-peptide exchange reaction and inhibits DM by binding tightly to the catalytic site and preventing MHCII access. This mechanism can help to discriminate among models that previously have been postulated for DO function. In human B cells, approximately half of the total cellular DM is associated with DO 18, 30 , leading to suggestions that DO might qualitatively alter DM activity-for example, by modulating its peptide specificity in certain cells types or developmental stages 21, 44 . However, the hypothetical DO-DM-MHCII ternary complex envisioned in these scenarios is not likely given the results presented here, as the DO-DM complex would be completely inactive in peptide loading and exchange reactions. A more attractive model has DO modulating the overall level of DM activity in a cell 45 , changing the peptide repertoire by skewing it toward a less constrained (that is, less DM-resistant or less DM-edited) set of peptides. DO-deficient B cells are deficient in presentation of antigens brought into the cell via surface immunoglobulin but not via fluid-phase endocytosis 28 , suggesting a role for DO in focusing DM's attention on antigen presentation pathways most relevant for B-cell function 21 . A potential mechanism based on differential inhibition of DM by DO in intracellular compartments with different pH 28 would seem to be ruled out by findings that DO can inhibit DM throughout the entire pH range in which DM is active 21, 31 . Thus, how DO regulates flux through the various intracellular antigen presentation pathways has not been clear. The results presented here, together with previous studies of the intracellular localization of DO, might provide a clue. A study using immunoelectron microscopy has found DO at the limiting perimeter membrane but not the internal membranes of the multivesicular bodies characteristic of MHCII-containing compartments (MIIC) in antigen-presenting cells 46 . Subsequent fluorescence resonance energy transfer (FRET) studies have revealed that the interaction of DM with MHCII is spatially regulated, with DM able to interact with MHCII only in internal vesicles and not in the limiting membrane 44 . Inhibition of DM by DO present only in the limiting membrane would explain this pattern. Recently, it has been observed in transfected cells that DO impairs the incorporation of DM into exosomes using a dileucine motif in the HLA-DOβ cytoplasmic tail 47 . As exosomes are believed to derive from internal vesicles released from multivesicular bodies by fusion with the plasma membrane, the same mechanism would be likely to retain DO-DM complexes in the limiting membrane. Thus, DO would be expected to inhibit DM throughout the endocytic pathway except for the internal compartments of the multivesicular bodies. These compartments would provide a DO-free zone for the preferential utilization of receptor-internalized antigens. Consistent with this idea, persisting antigens internalized into nonterminal late endosomes via B-cell receptor uptake show a higher degree of colocalization with DM than with DO 48 .
The structure of HLA-DO provides insight into the nature of αβ subunit association for both classical and nonclassical MHCII proteins and helps to explain the observed effects of αPro10a substitution on DO stability and trafficking. The hydrogen bonding network in the intersubunit region at the center of the β-sheet platform below the helices seems to be important in the stability and assembly of the classical MHCII αβ dimer 49 . In general, studies have shown that MHCII proteins with mismatched subunits are retained in the ER 50 . Substitution of αPro10a by valine or alanine allows DO to egress the ER in the absence of DM. The requirement of DM for DO to egress the ER has been interpreted as a structural defect that is compensated by DM 35 . We suggest that replacement of αPro10a, or of DOα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] with DRα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] (ref. 35) , restores the canonical continuous hydrogen bonding in this region and stabilizes DO αβ chain pairing. The interface with DM involves large portions of the lateral surface of both the DO α and β subunits, with interactions distributed broadly between the β-sheet platform and Ig domains. The chaperone-like function of DM in regulating DO transport is likely to result from cooperative interactions between these sites leading to stabilization of DO αβ pairing. The chaperone-like effect of DM in stabilizing classical MHCII proteins in the absence of peptide 11,12,51 might work by a similar mechanism. npg a r t i c l e s Despite the structural similarity of DO to classical MHCII proteins and strong conservation of the interface residues, DM binds tightly and essentially irreversibly to DO, but only transiently to MHCII. The structure reported here provides insight into how DO has adapted the generic MHCII structure for irreversible binding and functional inhibition of DM. First, the αPro10a β-bulge mentioned above disrupts DO αβ chain pairing and enforces a requirement for DM binding 35 . In the absence of peptide, MHCII proteins also are relatively unstable unless chaperoned by DM 11, 12 . This is particularly true for variants such as HLA-DQ and I-A that share the β-bulge at residue α10a. Second, DO seems not to bind peptide or other ligands, despite having a membrane-distal groove sharing many characteristics of the classical MHCII peptide-binding groove. For MHCII proteins, release from DM is thought to result from conformational changes induced by peptide binding 6, 9, 52 . It is possible that DO remains locked in a DM-binding conformation because it cannot bind peptide and access peptide-induced conformational changes. In classical MHCII-peptide complexes, the key DM-interacting residues αTrp43 and αPhe51 are largely inaccessible, but studies of conformational changes around the 3 10 helix and P1 pocket, as observed in the structure of DR1 mutant αF54C (DR1 is an allelic variant of DR; the mutant has increased DM interaction) 9 and in a molecular dynamics simulation of peptide-free MHCII 53 , provide a framework for understanding how MHCII conformational changes can expose these residues and couple DM binding with MHCII peptide release. However, it is important to note that although αTrp43 and αPhe51 are conserved in DO and have prominent roles in the DO-DM interface, the three-dimensional structure of free DO is not known. Thus, further studies will be required to determine whether the tighter DM binding of DO as compared to MHCII is due to differences in the static structures or to structural changes induced in DO upon binding DM.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Protein Data Bank: Crystallographic data and atomic coordinates have been deposited with accession code 4I0P.
